Theratechnologies -CMO, Dr. Christian Marsolais
CMO, Dr. Christian Marsolais
Source: Theratechnologies Inc.
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Theratechnologies Inc. (TH) provided an update on the dose increase portion of the TH1902 phase 1 clinical safety study
  • TH1902 is undergoing its first-in-human study linked to docetaxel for the treatment of sortilin-expressing cancers
  • Early efficacy signals in heavily pretreated patients were reported in the study
  • 18 heavily pre-treated patients, were enrolled, two which remain on treatment
  • Theratechnologies Inc. (TH) is up 11.79 per cent trading at $2.94 per share as of 2:13 p.m. ET

Theratechnologies Inc. (TH) provided an update on the dose increase portion of the TH1902 phase 1 clinical safety study.

The company stated TH1902 is undergoing its first-in-human study linked to docetaxel for the treatment of sortilin-expressing cancers. It has received fast-track designation from the United States Food and Drug Administration (FDA).

“The pharmacokinetics data observed in humans showed low levels of free docetaxel, consistent with what was observed in the prior animal studies, leading to a better safety profile… We see this as a nod to TH1902’s safety profile,” Dr. Christian Marsolais, CMO of Theratechnologies, said.

The company reported it has seen early efficacy signals in heavily pretreated patients during this dose escalation study.

“The first patient achieved a confirmed partial response with the tumor mass reduction of 53 per cent, and the other patient achieved a PSA response with stabilization of disease without any further progression,” said Dr. Satish Shah of the Pennsylvania Cancer Specialist and Research Institute.

Theratechnologies also reported efficacy with an endometrial cancer patient.

“She achieved prolonged stabilization of disease, over a 33-week period, without further progression, and was able to receive 11 cycles of treatment… This is a clinically meaningful result in late-stage disease with very limited treatment options,” Dr. Shah said.

An alleged 18 heavily pre-treated patients, who received an average of eight prior cancer treatments, were enrolled in the dose escalation portion of the study. Two which remain on treatment.

Theratechnologies Inc. (TH) is up 11.79 per cent trading at $2.94 per share as of 2:13 p.m. ET.


More From The Market Herald
Medicenna - President and CEO, Fahar Merchant.

" Medicenna (TSX:MDNA) closes US$20 million public offering

Medicenna Therapeutics Corp. (MDNA) has closed its

" Titan Medical (TSX:TMD) reports Q2 2022 financial results

Titan Medical (TMD) released financial results for the three and six months ended June 30, 2022.

" Aleafia Health (TSX:AH) earns record quarter-over-quarter revenue in Q1 2023

Aleafia Health (AH) reported its financial results for the three months ended June 30, 2022.

" UniDoc (CSE:UDOC) signs agreement to provide telehealth services in Kenya

UniDoc Health (UDOC) has signed a master equipment deployment and services agreement with Claron Health to provide telehealth services in Kenya.